Amylyx Pharmaceuticals' (AMLX) Relyvrio Receives Approval from FDA
(Updated - September 29, 2022 4:47 PM EDT)
Amylyx Pharmaceuticals' (NASDAQ: AMLX) Relyvrio received approval from the FDA for treatment of amyotrophic lateral sclerosis in adults.
The PDF could not be displayed inside the page, click here to open.